Company news

Genmab A/S news in 2025

Genmab A/S's news releases, calls and decks from 2025, newest first.

View company

Genmab Portfolio Prioritization Update

December 29, 2025

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

December 12, 2025

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

December 11, 2025

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

December 8, 2025

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

December 7, 2025

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

December 6, 2025

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

December 3, 2025

Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami

November 24, 2025

Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility

November 18, 2025

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

November 18, 2025

Medicxi Announces €500 Million Fund V

November 14, 2025

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

November 10, 2025

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility

November 10, 2025

Genmab Announces Financial Results for the Nine Months of 2025

November 6, 2025

Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London

November 5, 2025

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

November 3, 2025

Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.

October 21, 2025

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

October 18, 2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

October 14, 2025

EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction

September 30, 2025

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

September 29, 2025

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

September 3, 2025

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference

August 26, 2025

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

August 19, 2025

Genmab Announces Financial Results for the First Half of 2025

August 7, 2025

iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments

July 24, 2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

July 16, 2025

Genmab Announces Changes to its Executive Committee

July 1, 2025

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

June 15, 2025

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

June 2, 2025

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

May 27, 2025

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

May 21, 2025

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

May 14, 2025

Genmab Announces Financial Results for the First Quarter of 2024

May 8, 2025

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

May 1, 2025

Calls in 2025

Decks in 2025